Psoriasis Clinical Trial

Predicting Medication Response for Autoimmune Disease

Summary

Coral is conducting a large study comparing and predicting the relative effectiveness of different medications for autoimmune patients.

Patients with Inflammatory Bowel Disease (IBD) who have been diagnosed with either Ulcerative Colitis or Crohn's Disease and are undergoing treatment are eligible to participate.

Patients with Rheumatoid Arthritis (RA) and Psoriasis (Ps) will also be enrolled.

A novel clinical test will be performed to predict the responsiveness of a particular patient to different immune modulating therapies used in these conditions.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis diagnosis
On or about to begin a treatment for condition above

Study is for people with:

Psoriasis

Estimated Enrollment:

200

Study ID:

NCT04995783

Recruitment Status:

Terminated

Sponsor:

Coral Genomics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Coral Genomics, Inc.
San Francisco California, 94107, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Estimated Enrollment:

200

Study ID:

NCT04995783

Recruitment Status:

Terminated

Sponsor:


Coral Genomics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.